PTC's brain-delivered gene therapy gets US nod for rare genetic disorder

PTC Therapeutics' gene therapy Kebilidi (eladocagene exuparvovec-tneq) was granted an accelerated approval by the FDA on Wednesday to treat aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder that impairs dopamine synthesis and leads to severe motor dysfunction.